A phase i study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Neuro-Oncology

Volumn 17, Issue 10, 2015, Pages 1386-1392

  Gerstner, Elizabeth R ^a,c   Ye, Xiaobu ^b   Duda, Dan G ^a   Levine, Michael A ^c   Mikkelsen, Tom ^d   Kaley, Thomas J ^e   Olson, Jeffrey J ^f   Nabors, Burt L ^g   Ahluwalia, Manmeet S ^h   Wen, Patrick Y ⁱ   Jain, Rakesh K ^a   Batchelor, Tracy T ^a   Grossman, Stuart ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

angiogenesis; biomarker; glioblastoma; invasion; treatment

Indexed keywords

CARBONATE DEHYDRATASE IX; CEDIRANIB; CILENGITIDE; PLACENTAL GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SNAKE VENOM; TUMOR MARKER;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CANCER RECURRENCE; COGNITIVE DEFECT; CONFUSION; DIARRHEA; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DUODENUM BLEEDING; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; MALE; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECURRENT GLIOBLASTOMA; SEIZURE; THROMBOCYTOPENIA; BLOOD; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SNAKE VENOMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943378844     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov085     Document Type: Article

References (25)

1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
2. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
4. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61(18):6624-6628.
5. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2(4):306-314.
6. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
7. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
8. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2):380-389, discussion 390.
9. Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18(3): 378-386.
10. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed Clin Oncol. 2010;28(16):2712-2718.
11. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15(4):392-400.
12. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012; 106(1):147-153.
13. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817-2823.
14. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
15. Radbruch A, Lutz K, Wiestler B, et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro-Oncol. 2012;14(2):222-229.
16. Nowosielski M, Wiestler B, Goebel G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684-1692.
17. Schaub C, Greschus S, Seifert M, et al. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology. 2013;85(3):191-195.
18. Gerstner ER, Chen PJ, Wen PY, et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010;12(5):466-472.
19. de Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more. Clin Cancer Res. 2011;17(19):6109-6111.
20. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18): 3027-3035.
21. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012;7(2):e26331.
22. Batchelor TT, Gerstner ER, Emblem KE, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA. 2013;110(47):19059-19064.
23. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma Soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:577-583.
24. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet. Oncol. 2014;15(10):1100-1108.
25. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212-3218.